The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols..
- Who it may be relevant to
- Registry conditions: Acute Ischemic Stroke. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study Protocol on the Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke
Overview
This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are: What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.
Interventions
- Combination product Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.
The conventional drug therapy includes anticoagulant, antiplatelet, antihypertensive and other drugs. The surgical therapy includes AIS intravenous thrombolysis or endovascular therapy.
Primary outcome measures
- Evaluate the recurrence, death, and bleeding events of stroke in the research subjects [Time frame: Follow up will be conducted at 3 months, 6 months, and 12 months after the patient's discharge, and the main outcome events mentioned above will be evaluated.]
Eligibility criteria
- Inclusion Criteria
(1) Inclusion Criteria for Acute Ischemic Stroke Patients:
- Aged between 18 and 85 years.
- Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).
- Acute onset, with symptoms occurring within 72 hours and being the first episode.
- Voluntary participation with signed informed consent.
(2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history).
- Exclusion Criteria
(1) Exclusion Criteria for Healthy Controls:
- Patients with cerebrovascular diseases occurring within 72 hours.
- Pregnant or lactating patients.
(2) Exclusion Criteria for Acute Ischemic Stroke Patients:
- Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.
- Patients with coagulation disorders or other hematologic diseases.
- Patients with severe cardiovascular, pulmonary, or hepatic diseases.
- Renal dysfunction.
- Cancer patients.
- Patients with active gastric ulcers or gastric bleeding.
- Pregnant or lactating patients.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Peking University Aerospace Center Hospital — Beijing
Identifiers
NCT: NCT07269288 · 2025017 · 2024PSPT0905100